aspirin has been researched along with Cancer of Colon in 280 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", mucosal prostaglandin E2 (PGE2) formation and transforming growth factor alpha (TGF-alpha) expression] in normal-appearing rectal mucosa from individuals with a history of adenomatous polyps." | 9.09 | Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. ( Barnes, CJ; Cameron, IL; Hamby-Mason, RL; Hardman, WE; Lee, M; Speeg, KV, 1999) |
| "To examine the relation between the use of aspirin and non-steroidal anti-inflammatory drugs and the presence of asymptomatic colorectal adenomas." | 9.07 | Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. ( Hardcastle, JD; Hawtin, PG; Little, J; Logan, RF, 1993) |
| "Despite being shown to be effective for chemoprevention of colorectal cancer, aspirin has limitations including adverse effects and inability to block colitis-associated colon cancer (CAC)." | 8.31 | Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells. ( Jiang, Q; Jones-Hall, Y; Liu, KY; Nakatsu, CH; Wang, Q, 2023) |
| " We investigated the time-dependent methylation drift in aspirin users and nonusers using multivariable regression and related the modulatory effect of aspirin to colonic epigenome-aging and CC." | 7.96 | Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging. ( Chaber-Ciopinska, A; Noreen, F; Regula, J; Schär, P; Truninger, K, 2020) |
| " In this study, we investigated the effects of long-term use (up to 25 years) of NSAIDs (ibuprofen or aspirin) on adenoma pathology and β-catenin-mediated signaling in sporadic human colon adenomas." | 7.77 | Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. ( Boardman, LA; Greenspan, EJ; Madigan, JP; Rosenberg, DW, 2011) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 7.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| " We assessed the cytotoxic activity of a new aspirin derivative, NCX 4016, after different exposure schedules, in three human colon adenocarcinoma cell lines." | 7.72 | NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. ( Amadori, D; Medri, L; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W, 2003) |
| "Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists." | 7.69 | Aspirin and the risk of colorectal cancer in women. ( Colditz, GA; Egan, KM; Giovannucci, E; Hunter, DJ; Speizer, FE; Stampfer, MJ; Willett, WC, 1995) |
| "Patients who reported taking aspirin on both questionnaires (consistent users) had a lower risk of new adenomas at their 1-year follow-up colonoscopy (odds ratio = 0." | 7.68 | Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. ( Baron, JA; Freeman, DH; Greenberg, ER; Haile, R; Mandel, JS, 1993) |
| "Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity." | 6.58 | [Aspirin and colorectal cancer]. ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| " Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen." | 5.51 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. ( Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019) |
| "Luteolin (LUT) has cancer prevention and anti-inflammatory effects." | 5.42 | Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats. ( Ahmed, ES; El-Waseef, AM; Osman, NH; Said, UZ, 2015) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 5.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| " Collectively, these two events, necrosis and cell cycle arrest, may contribute to the chemopreventive effect that seems to result from long-term administration of aspirin in vivo." | 5.30 | Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. ( Frommel, TO; Subbegowda, R, 1998) |
| "Aspirin has also been shown to inhibit cell proliferation in human tumor cell lines and to induce apoptosis in colonic mucosa of familial polyposis patients." | 5.30 | Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. ( Acquaviva, AM; Apicella, A; Di Popolo, A; Memoli, A; Pignata, S; Ricchi, P; Zarrilli, R, 1997) |
| "311 subjects with single/multiple colorectal adenomas and adenocarcinomas excised by endoscopy were enrolled in the study (152 patients in the aspirin group and 159 patients in the placebo group)." | 5.19 | The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. ( Abe, T; Gondo, N; Goto, C; Iimuro, M; Ishikawa, H; Joh, T; Kitamura, S; Kudo, SE; Kusunoki, M; Lee, K; Matsuda, T; Matsuura, N; Mizuno, M; Mutoh, M; Okamura, S; Saida, Y; Sakai, T; Sano, Y; Sato, Y; Sugimoto, K; Suzuki, S; Tajika, M; Takayama, T; Tanaka, S; Tokudome, S; Wakabayashi, K; Yukawa, T, 2014) |
| ", mucosal prostaglandin E2 (PGE2) formation and transforming growth factor alpha (TGF-alpha) expression] in normal-appearing rectal mucosa from individuals with a history of adenomatous polyps." | 5.09 | Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. ( Barnes, CJ; Cameron, IL; Hamby-Mason, RL; Hardman, WE; Lee, M; Speeg, KV, 1999) |
| "To examine the relation between the use of aspirin and non-steroidal anti-inflammatory drugs and the presence of asymptomatic colorectal adenomas." | 5.07 | Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. ( Hardcastle, JD; Hawtin, PG; Little, J; Logan, RF, 1993) |
| "In rodents, nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin inhibit chemically induced adenomas and early carcinomas of the colon." | 4.79 | Aspirin and gastrointestinal cancer. ( Thun, MJ, 1997) |
| "Despite being shown to be effective for chemoprevention of colorectal cancer, aspirin has limitations including adverse effects and inability to block colitis-associated colon cancer (CAC)." | 4.31 | Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells. ( Jiang, Q; Jones-Hall, Y; Liu, KY; Nakatsu, CH; Wang, Q, 2023) |
| "The role of chronic inflammation and arachidonic acid (AA) metabolism in tumor progression has been well characterized for variety of cancers, with compelling data for colon cancer." | 4.12 | Targeting the Leukotriene Pathway for Colon Cancer Interception. ( Mohammed, A; Shoemaker, RH, 2022) |
| " We investigated the time-dependent methylation drift in aspirin users and nonusers using multivariable regression and related the modulatory effect of aspirin to colonic epigenome-aging and CC." | 3.96 | Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging. ( Chaber-Ciopinska, A; Noreen, F; Regula, J; Schär, P; Truninger, K, 2020) |
| " This study investigated the protective role of ASA in azoxymethane (AOM)-initiated and dextran sulfate sodium (DSS)-promoted colitis-associated colon cancer (CAC) and examined the epigenetic effects, particularly on histone 3 lysine 27 acetylation (H3K27ac), underlying the preventive effect of ASA." | 3.83 | The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice. ( Guo, Y; Huang, MT; Kong, AN; Li, W; Liu, Y; Su, ZY; Zhang, C, 2016) |
| " In this study, we investigated the effects of long-term use (up to 25 years) of NSAIDs (ibuprofen or aspirin) on adenoma pathology and β-catenin-mediated signaling in sporadic human colon adenomas." | 3.77 | Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. ( Boardman, LA; Greenspan, EJ; Madigan, JP; Rosenberg, DW, 2011) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 3.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| "05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium." | 3.74 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007) |
| "Warfarin and aspirin are commonly used to prevent cardiovascular diseases." | 3.73 | [Characteristics of colon cancer diagnosed in patients taking aspirin or warfarin]. ( Kim, BC; Kim, S; Kim, TI; Kim, WH; Park, S; Shin, SJ, 2005) |
| " We assessed the cytotoxic activity of a new aspirin derivative, NCX 4016, after different exposure schedules, in three human colon adenocarcinoma cell lines." | 3.72 | NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. ( Amadori, D; Medri, L; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W, 2003) |
| "We investigated the primary adenoma cells and HT-29 cells in an attempt to know whether NaBT and two NSAIDs (aspirin and NS-398) could be used as effective adjuvant for reducing cell proliferation, and to explore the possible mechanisms therein involved." | 3.72 | [Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2003) |
| "Adenocarcinoma cells HT-29 were used to investigate whether butyrates and non-steroidal anti-inflammatory agents (NSAIDs, aspirin and NS-398) would be effective adjuvants for inducing apoptosis and to probe its possible mechanisms." | 3.71 | [The effects of butyrates and non-steroidal anti-inflammatory agents on HT-29 colonic carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2002) |
| " We evaluated the effect of aspirin (ASA) and three other structurally unrelated NSAIDs (indomethacin, naproxen, and piroxicam) on cell proliferation, cell cycle phase distribution, and the development of apoptosis in HT-29 colon adenocarcinoma cells in vitro." | 3.69 | Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. ( Koutsos, MI; Qiao, L; Rigas, B; Shiff, SJ, 1996) |
| "Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists." | 3.69 | Aspirin and the risk of colorectal cancer in women. ( Colditz, GA; Egan, KM; Giovannucci, E; Hunter, DJ; Speizer, FE; Stampfer, MJ; Willett, WC, 1995) |
| "Patients who reported taking aspirin on both questionnaires (consistent users) had a lower risk of new adenomas at their 1-year follow-up colonoscopy (odds ratio = 0." | 3.68 | Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. ( Baron, JA; Freeman, DH; Greenberg, ER; Haile, R; Mandel, JS, 1993) |
| "Beta-carotene's effect on cancer over nearly 13 years was examined overall and within subgroups defined by baseline characteristics using proportional-hazards models." | 2.69 | Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). ( Buring, JE; Cook, NR; Hennekens, CH; Le, IM; Manson, JE, 2000) |
| " Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer." | 2.65 | Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. ( Dixon, R; Gordon, R; Hamilton, R; Harvey, H; Heckard, R; Lipton, A; Ramsey, H; Scialla, S; Weltz, M; White, D, 1982) |
| "Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity." | 2.58 | [Aspirin and colorectal cancer]. ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| " However, obstacles to using phytochemicals for chemoprevention, including bioavailability and translational potential, must be resolved." | 2.58 | Could Aspirin and Diets High in Fiber Act Synergistically to Reduce the Risk of Colon Cancer in Humans? ( Arnold, M; Huang, YW; Oshima, K; Pan, P; Wang, LS; Yearsley, M; Yu, J; Zhang, J, 2018) |
| "In lay terms "cancers follow bleeding", which seems to be true for antithrombotic agents in general." | 2.52 | Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. ( Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL, 2015) |
| "In the model estrogen-independent breast cancer, lunasin and aspirin administration inhibits cell proliferation, arrest cell cycle in S-phase as well as a decreases expression of cancer genes." | 2.50 | [Lunasin--a novel chemopreventive peptide]. ( Kuźmicz, I; Markowska, A; Wołosik, K, 2014) |
| "In spite of improvements in care of colon cancer patients, prevention may enable potential patients to avoid cancer therapy." | 2.45 | Nutrition and colon cancer prevention. ( Marshall, JR, 2009) |
| "Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants." | 2.45 | Aspirin, salicylates, and cancer. ( Duthie, GG; Elwood, PC; Gallagher, AM; Morgan, G; Mur, LA, 2009) |
| " However, long-term use of NSAIDs is associated with substantial gastrointestinal toxicity and may cause an exacerbation in IBD patients." | 2.43 | Chemoprevention for colon cancer: new opportunities, fact or fiction? ( Mulder, CJ; Terhaar Sive Droste, JS; Tuynman, JB; Van Dullemen, HM, 2006) |
| "Loss of function of the adenomatous polyposis coli (APC) tumour suppressor gene through truncating mutations or other means is an early event in most colo-rectal cancer (CRC)." | 2.42 | Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. ( Bishop, DT; Burn, J; Chapman, PC; Mathers, JC; Mickleburgh, I, 2003) |
| "Colorectal cancer (CRC) can be either prevented or alleviated using conventional drugs combined with natural treatments." | 1.72 | Andean berry (Vaccinium meridionale Swartz) juice, in combination with Aspirin, displayed antiproliferative and pro-apoptotic mechanisms in vitro while exhibiting protective effects against AOM-induced colorectal cancer in vivo. ( Arango-Varela, SS; Luzardo-Ocampo, I; Maldonado-Celis, ME, 2022) |
| "Aspirin (ASA) has attracted wide interest of numerous scientists worldwide thanks to its chemopreventive and chemotherapeutic effects, particularly in colorectal cancer (CRC)." | 1.56 | New Formulation of a Methylseleno-Aspirin Analog with Anticancer Activity towards Colon Cancer. ( Aydillo, C; Encío, I; González-Gaitano, G; Plano, D; Ruberte, AC; Sanmartín, C; Sharma, AK, 2020) |
| " Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen." | 1.51 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. ( Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019) |
| "Highly Active Metastasis Preventing Therapy (HAMPT) is a quardruple drug combination consisting of mifepristone, aspirin, lysine and doxycycline." | 1.51 | HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept. ( Jia, L; Liu, J; Wan, L; Xu, H; Xu, J; Zheng, N, 2019) |
| "Use of aspirin after diagnosis of colon cancer has been associated with improved survival." | 1.46 | The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. ( Bastiaannet, E; Frouws, MA; Kuppen, PJ; Lemmens, VE; Liefers, GJ; Morreau, H; Prinse, B; Reimers, MS; Swets, M; van de Velde, CJ; van Eijk, R; van Herk-Sukel, MP; van Wezel, T, 2017) |
| "In this study, using colon cancer as an example, we provide both in vitro (cell culture) and in vivo (chemically induced mouse model of colon cancer) evidence that this profound antineoplastic action may be associated with aspirin's ability to irreversibly inhibit COX-1-mediated platelet activation, thereby blocking platelet-cancer cell interactions, which promote cancer cell number and invasive potential." | 1.46 | Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. ( Bergeron, AL; Bick, RJ; Dial, EJ; Fang, D; Lichtenberger, LM; Phan, T; Poindexter, BJ; Pradhan, S; Vijayan, KV, 2017) |
| "For our study, we used two colon cancer cell lines isolated from the same donor but characterized by different metastatic potential, SW480 (nonmetastatic) and SW620 (metastatic) cancer cells, and a pancreatic cancer cell line, PANC-1 (nonmetastatic)." | 1.46 | Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC. ( McCarty, OJ; Mitrugno, A; Ngo, AT; Pang, J; Sears, RC; Sylman, JL; Williams, CD, 2017) |
| "Aspirin users were more likely to be older (median: 76." | 1.46 | Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer. ( Christie, M; Desai, J; Gibbs, P; Hutchinson, R; Lee, B; Lunke, S; Murphy, C; Sinnathamby, M; Skinner, I; Tie, J; Tran, B; Turner, N; Waring, P; Wong, HL, 2017) |
| "Aspirin's ability to inhibit cell proliferation and induce apoptosis in cancer cell lines is considered to be an important mechanism for its anti-cancer effects." | 1.43 | Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53. ( Ai, G; Alfonso, LF; Bhat, GJ; Dachineni, R; Kumar, DR; Marimuthu, S, 2016) |
| "Luteolin (LUT) has cancer prevention and anti-inflammatory effects." | 1.42 | Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats. ( Ahmed, ES; El-Waseef, AM; Osman, NH; Said, UZ, 2015) |
| "For both colon and rectal cancer, increasing numbers of risk alleles were associated with increased hazard of death from cancer; the estimated hazard of death for colon cancer for the highest category of risk alleles was 1." | 1.39 | Interleukin genes and associations with colon and rectal cancer risk and overall survival. ( Bondurant, KL; Herrick, JS; Kadlubar, S; Lundgreen, A; Slattery, ML; Wolff, RK, 2013) |
| "Aspirin use after the diagnosis of colon cancer in older adults was associated with longer survival." | 1.38 | Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. ( Bastiaannet, E; de Craen, AJ; Lemmens, VE; Liefers, GJ; Reimers, MS; van de Velde, CJ; van den Broek, CB; van Herk-Sukel, MP, 2012) |
| "Two SNPs in TXNRD3 were associated with rectal cancer (rs11718498 dominant OR 1." | 1.38 | Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. ( Corcoran, C; Lundgreen, A; Slattery, ML; Welbourn, B; Wolff, RK, 2012) |
| "Aspirin/NSAID use was classified as none, prediagnosis and postdiagnosis and only postdiagnosis." | 1.38 | Use of aspirin postdiagnosis improves survival for colon cancer patients. ( Bastiaannet, E; Coebergh, JW; de Craen, AJ; Dekkers, OM; Fodde, R; Herings, RM; Lemmens, V; Liefers, GJ; Sampieri, K; van de Velde, CJ; van den Broek, CB; van Herk-Sukel, MP, 2012) |
| " However, their long-term use is associated with adverse gastrointestinal effects." | 1.38 | NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. ( Chattopadhyay, M; Kashfi, K; Kodela, R; Olson, KR, 2012) |
| "Five colon cancer and two adenoma cell lines, human ex vivo adenomas and normal colonic epithelium were treated with aspirin or sulindac combined with rhTRAIL." | 1.37 | TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. ( de Jong, S; de Vries, EG; Heijink, DM; Hollema, H; Jalving, M; Kleibeuker, JH; Koornstra, JJ; Koster, R; Oosterhuis, D; Sloots, IA, 2011) |
| "Aspirin use decreases colon cancer risk, but this association may vary among population subgroups." | 1.37 | Aspirin use, body mass index, physical activity, plasma C-peptide, and colon cancer risk in US health professionals. ( Chan, AT; Fuchs, CS; Giovannucci, EL; Smith-Warner, SA; Spiegelman, D; Willett, WC; Wu, K; Zhang, X, 2011) |
| "The purpose of this work was to assess synergistic inhibitory responses of a novel chemopreventive combination regimen of drugs namely, aspirin in combination with calcium and folic acid on two human colon cancer cell lines, HT-29 and SW-480." | 1.36 | Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. ( Chaudhary, A; Kanthamneni, N; Prabhu, S; Wang, J, 2010) |
| " Related to the salicin content of the willow bark extract, a higher dosage of ASA was needed." | 1.36 | In vitro anti-proliferative effects of the willow bark extract STW 33-I. ( Bonaterra, GA; Kelber, O; Kinscherf, R; Metz, J; Weiser, D, 2010) |
| " We investigated the long-term administration of low dose of aspirin in a model of experimental colon carcinogenesis in rats." | 1.36 | Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. ( Bouhadjar, M; Bousserouel, S; Gosse, F; Marescaux, J; Raul, F; Soler, L, 2010) |
| "Using data from a large study of colon cancer, we examine genetic variants in insulin, inflammation, estrogen, metabolizing enzymes, and energy homeostasis genes to explore associations with microsatellite instability (MSI), CpG Island methylator phenotype (CIMP), mutations of p53 in exons 5 through 8, and mutations in codons 12 and 13 of Ki-ras." | 1.35 | Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. ( Caan, BJ; Curtin, K; Fitzpatrick, F; Herrick, J; Potter, JD; Samowitz, WS; Slattery, ML; Wolff, RK, 2009) |
| "98) in a dose-response fashion (P for linear trend across genotypes = 0." | 1.35 | Transcription factor 7-like 2 polymorphism and colon cancer. ( Caan, BJ; Folsom, AR; Herrick, J; Potter, JD; Slattery, ML; Wolff, R, 2008) |
| "We observed a slight reduction in colon cancer risk with the AA LEP rs2167270 genotype (OR 0." | 1.35 | Leptin and leptin receptor genotypes and colon cancer: gene-gene and gene-lifestyle interactions. ( Caan, BJ; Herrick, J; Potter, JD; Slattery, ML; Wolff, RK, 2008) |
| "Variant CYP2C9 genotypes enhanced the protective effect of ibuprofen on the prevention of colorectal cancer, and a dose-response relationship with respect to increasing numbers of variant alleles was seen (P interaction = ." | 1.33 | Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. ( Andersen, K; Curtin, K; Levin, TR; Ma, KN; Samowitz, WS; Slattery, ML; Sweeney, C; Wolff, RK, 2006) |
| "For proximal colon cancer, the multivariable-adjusted HRs for women reporting use of aspirin or non-aspirin NSAIDs two or more times weekly (compared with nonusers of each) were 0." | 1.33 | Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. ( Anderson, KE; Folsom, AR; Limburg, PJ; Mahipal, A, 2006) |
| "The proliferation of colon cancer cells was determined by MTT assay, and the cell cycle progression was analyzed by flow cytometric assay." | 1.33 | [Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells]. ( Huang, MH; Li, X; Ouyang, Q; Tang, CW; Wang, CH, 2006) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 1.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "Conventional aspirin prevents human colon cancer, but its toxicity precludes its application as a chemopreventive agent." | 1.33 | Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. ( Hundley, TR; Rigas, B, 2006) |
| "Aspirin treatment led to the activation of NF-kappaB signalling and increased binding at these NF-kappaB sites in the SSAT promoter, hence providing a potential mechanism for the induction of SSAT by aspirin in these cells." | 1.33 | Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. ( Babbar, N; Casero, RA; Gerner, EW, 2006) |
| "Rofecoxib in lower doses had the same effect on adenomas (p < 0." | 1.33 | Cyclooxygenase-2 inhibition in colon experimental carcinogenesis. ( Amengual Antich, I; Gamundí Gamundí, A; Ibarra de la Rosa, J; Noguera Aguilar, JF; Plaza Martínez, A; Pujol Tugores, JJ; Tortajada Collado, C, 2005) |
| "NO-ASA inhibits colon cancer cell growth several hundred times more potently than does ASA." | 1.33 | Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. ( Gao, J; Liu, X; Rigas, B, 2005) |
| "Data were available from 1,577 cases of colon cancer that were matched to 1,971 population-based controls and 794 cases of rectal cancer that were matched to 1,001 population-based controls." | 1.33 | PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). ( Curtin, K; Levin, TR; Ma, KN; Murtaugh, M; Potter, JD; Samowitz, W; Slattery, ML; Sweeney, C; Wolff, R, 2006) |
| " Chronic use of high doses of these agents may induce side effects in ostensibly normal individuals." | 1.33 | Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. ( Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X, 2006) |
| "NO-ASA inhibits colon cancer cell growth more potently than ASA by inhibiting cell proliferation and enhancing cell killing." | 1.32 | Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemopreventi ( Chen, J; Gao, J; Hundley, TR; Kashfi, K; Kopelovich, L; Nath, N; Rigas, B; Williams, JL, 2003) |
| "Aspirin treatment (10 mg/kg of body weight per day) reduced eNOS expression, but failed to modify the expression of VEGF in the colonic tissue of azoxymethane-treated rats." | 1.32 | Aspirin inhibits endothelial nitric oxide synthase (eNOS) and Flk-1 (vascular endothelial growth factor receptor-2) prior to rat colon tumour development. ( Abarrategui, C; Carrasco, C; Escribano, M; García-Mendez, A; López-Farré, A; Manzarbeitia, F; Martín, MJ; Molero, L; Porres Cubero, JC; Rico, L; Sánchez-Fayos, P; Vázquez, M, 2004) |
| "The aspirin effects were apparently unrelated to prostaglandin biosynthesis inhibition, since although these cells were found to express high levels of cyclooxygenase 1 (COX-1) and low levels of COX-2 proteins, they did not produce any measurable net amounts of prostaglandins, based on both utilization of radiolabelled arachidonic acid and the radioimmunoassay of prostaglandins E2 and F2 alpha." | 1.32 | Prostaglandin-independent effects of aspirin on cell cycle and putrescine synthesis in human colon carcinoma cells. ( Andriamihaja, M; Blachier, F; Camous, S; Charpigny, G; Eklou-Kalonji, E; Mayeur, C; Reinaud, P; Robert, V, 2003) |
| "We found that colon cancer medium-induced COX-2 protein expression in EC and aspirin or sodium salicylate suppressed the cancer-induced COX-2 protein levels at concentrations correlated with those that suppressed endothelial tube formation." | 1.32 | Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. ( Juneja, HS; Lee, S; Shtivelband, MI; Wu, KK, 2003) |
| "Aspirin has also been shown to inhibit cell proliferation in human tumor cell lines and to induce apoptosis in colonic mucosa of familial polyposis patients." | 1.30 | Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. ( Acquaviva, AM; Apicella, A; Di Popolo, A; Memoli, A; Pignata, S; Ricchi, P; Zarrilli, R, 1997) |
| "Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in carcinogen-initiated cells." | 1.30 | Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. ( Barnes, CJ; Cameron, IL; Hardman, WE; Lee, M, 1998) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| " Collectively, these two events, necrosis and cell cycle arrest, may contribute to the chemopreventive effect that seems to result from long-term administration of aspirin in vivo." | 1.30 | Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. ( Frommel, TO; Subbegowda, R, 1998) |
| "Colorectal cancer is the second leading cause of death from cancer in The United States." | 1.30 | Colorectal cancer--chemoprevention. ( Boone, WT, 1998) |
| "Aspirin use was protective for colorectal cancer (odds ratio, 0." | 1.30 | Association between coronary heart disease and cancers of the breast, prostate, and colon. ( Ahsan, H; Chen, L; Hagan, M; Jacobson, JS; Khan, ZR; Neugut, AI; Pablos-Mendez, A; Rahman, MI; Rosenberg, DJ; Shea, S; Wahid, N, 1998) |
| " It appears that 325 mg of aspirin is sufficient to affect PGE2 production and that increasing the dosage to 650 mg daily provides an additional decrease in PGE2 synthesis." | 1.30 | Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. ( Dyavanapalli, M; Frommel, TO; Kazi, N; Liao, Y; Lietz, H; Mobarhan, S; Oldham, T, 1997) |
| "The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels." | 1.30 | Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. ( Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999) |
| " Results indicate that only aspirin treatment throughout the entire carcinogenic period significantly reduced tumour incidence and volume whereas intermittent aspirin dosing increased tumour number and/or volume, suggesting that aspirin must be used for an extended period in order to gain any chemopreventive benefit." | 1.30 | Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in rats. ( Barnes, CJ; Lee, M, 1999) |
| "We have observed that in human colon cancer the expression of HLA class I and II antigens is reduced or lost; loss of HLA antigens is suspected to be a mechanism by which the malignant cell escapes the immune surveillance." | 1.29 | Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. ( Arvind, P; Duceman, B; Lovelace, CI; Papavassiliou, ED; Qiao, L; Rigas, B; Tsioulias, GJ, 1995) |
| "Colorectal cancer is the second leading cause of death from cancer in the United States." | 1.29 | G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. ( Beauchamp, RD; DuBois, RN; Shao, J; Sheng, H; Tsujii, M, 1996) |
| " The difference between the two disease groups from the same VA patient population suggests that chronic use of NSAID truly protects against future development of colon cancer." | 1.29 | Diseases preceding colon cancer. A case-control study among veterans. ( Müller, AD; Sonnenberg, A; Wasserman, IH, 1994) |
| "We have reported reduced risk of fatal colon cancer among persons who used aspirin in a large prospective study." | 1.29 | Aspirin use and risk of fatal cancer. ( Calle, EE; Flanders, WD; Heath, CW; Namboodiri, MM; Thun, MJ, 1993) |
| "Death rates from colon cancer were measured through 1988." | 1.28 | Aspirin use and reduced risk of fatal colon cancer. ( Heath, CW; Namboodiri, MM; Thun, MJ, 1991) |
| "The gastric ulcer is easily detected by a barium meal study although a barium enema may be necessary to show the fistulous communication." | 1.26 | Gastrocolic fistula as a complication of benign gastric ulcer. ( Laufer, I; Stolberg, H; Thornley, GD, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (2.14) | 18.7374 |
| 1990's | 79 (28.21) | 18.2507 |
| 2000's | 101 (36.07) | 29.6817 |
| 2010's | 81 (28.93) | 24.3611 |
| 2020's | 13 (4.64) | 2.80 |
| Authors | Studies |
|---|---|
| Kalgutkar, AS | 2 |
| Kozak, KR | 1 |
| Crews, BC | 2 |
| Hochgesang, GP | 1 |
| Marnett, LJ | 5 |
| Liu, W | 1 |
| Zhou, J | 1 |
| Zhang, T | 1 |
| Zhu, H | 1 |
| Qian, H | 1 |
| Zhang, H | 1 |
| Huang, W | 1 |
| Gust, R | 1 |
| Bhardwaj, A | 1 |
| Kaur, J | 1 |
| Sharma, SK | 1 |
| Huang, Z | 1 |
| Wuest, F | 1 |
| Knaus, EE | 1 |
| Arango-Varela, SS | 1 |
| Luzardo-Ocampo, I | 1 |
| Maldonado-Celis, ME | 1 |
| Mohammed, A | 2 |
| Shoemaker, RH | 1 |
| Liu, KY | 1 |
| Wang, Q | 1 |
| Nakatsu, CH | 1 |
| Jones-Hall, Y | 1 |
| Jiang, Q | 1 |
| Janakiram, NB | 1 |
| Madka, V | 1 |
| Zhang, Y | 2 |
| Singh, A | 1 |
| Biddick, L | 1 |
| Li, Q | 1 |
| Lightfoot, S | 1 |
| Steele, VE | 5 |
| Lubet, RA | 3 |
| Suen, CS | 1 |
| Miller, MS | 1 |
| Sei, S | 1 |
| Rao, CV | 4 |
| Kwon, S | 1 |
| Chan, AT | 5 |
| Khan, AA | 1 |
| Murtaza, G | 1 |
| Khalid, M | 1 |
| Finniss, M | 1 |
| Helton, T | 1 |
| Salla, M | 1 |
| Pandya, V | 1 |
| Bhullar, KS | 1 |
| Kerek, E | 1 |
| Wong, YF | 1 |
| Losch, R | 1 |
| Ou, J | 1 |
| Aldawsari, FS | 1 |
| Velazquez-Martinez, C | 1 |
| Thiesen, A | 1 |
| Dyck, JRB | 1 |
| Hubbard, BP | 1 |
| Baksh, S | 1 |
| Noreen, F | 1 |
| Chaber-Ciopinska, A | 1 |
| Regula, J | 1 |
| Schär, P | 1 |
| Truninger, K | 1 |
| Prizment, AE | 2 |
| Onyeaghala, GC | 1 |
| Church, TR | 2 |
| O'Grady, J | 1 |
| Quigley, EMM | 1 |
| Li, S | 1 |
| Peng, F | 1 |
| Hua, L | 1 |
| Xue, L | 1 |
| Onyeaghala, G | 1 |
| Ruberte, AC | 1 |
| González-Gaitano, G | 1 |
| Sharma, AK | 1 |
| Aydillo, C | 1 |
| Encío, I | 1 |
| Sanmartín, C | 1 |
| Plano, D | 1 |
| Harewood, R | 1 |
| Disney, R | 1 |
| Kinross, J | 1 |
| von Wagner, C | 1 |
| Cross, AJ | 1 |
| Grancher, A | 1 |
| Michel, P | 2 |
| Di Fiore, F | 2 |
| Sefrioui, D | 1 |
| Bains, SJ | 1 |
| Mahic, M | 1 |
| Myklebust, TÅ | 1 |
| Småstuen, MC | 1 |
| Yaqub, S | 1 |
| Dørum, LM | 1 |
| Bjørnbeth, BA | 1 |
| Møller, B | 1 |
| Brudvik, KW | 1 |
| Taskén, K | 1 |
| Pan, P | 1 |
| Huang, YW | 1 |
| Oshima, K | 1 |
| Yearsley, M | 1 |
| Zhang, J | 1 |
| Yu, J | 1 |
| Arnold, M | 1 |
| Wang, LS | 1 |
| Boige, V | 1 |
| Andre, T | 1 |
| Aparicio, T | 1 |
| Bachet, JB | 1 |
| Dahan, L | 1 |
| Guimbaud, R | 1 |
| Lepage, C | 1 |
| Manfredi, S | 1 |
| Tougeron, D | 1 |
| Taieb, J | 1 |
| Selves, J | 1 |
| Le Malicot, K | 1 |
| Maillard, E | 1 |
| Barry, EL | 1 |
| Fedirko, V | 1 |
| Baron, JA | 4 |
| Christudoss, P | 2 |
| Chacko, G | 1 |
| Selvakumar, R | 2 |
| Fleming, JJ | 2 |
| Pugazhendhi, S | 1 |
| Mathew, G | 2 |
| Jovani, M | 1 |
| Xu, H | 2 |
| Wan, L | 1 |
| Xu, J | 1 |
| Liu, J | 1 |
| Zheng, N | 1 |
| Jia, L | 1 |
| Bonaterra, GA | 2 |
| Kelber, O | 2 |
| Weiser, D | 2 |
| Kinscherf, R | 2 |
| Fink, SP | 2 |
| Yang, DH | 1 |
| Barnholtz-Sloan, JS | 2 |
| Ryu, YM | 1 |
| Mikkola, D | 1 |
| Potter, JD | 9 |
| Lampe, JW | 2 |
| Markowitz, SD | 2 |
| Myung, SJ | 1 |
| Lai, SW | 1 |
| Liao, KF | 1 |
| Pulimood, AB | 1 |
| Ishikawa, H | 1 |
| Mutoh, M | 1 |
| Suzuki, S | 1 |
| Tokudome, S | 1 |
| Saida, Y | 1 |
| Abe, T | 1 |
| Okamura, S | 1 |
| Tajika, M | 1 |
| Joh, T | 1 |
| Tanaka, S | 1 |
| Kudo, SE | 1 |
| Matsuda, T | 1 |
| Iimuro, M | 1 |
| Yukawa, T | 1 |
| Takayama, T | 1 |
| Sato, Y | 1 |
| Lee, K | 1 |
| Kitamura, S | 1 |
| Mizuno, M | 1 |
| Sano, Y | 1 |
| Gondo, N | 1 |
| Sugimoto, K | 1 |
| Kusunoki, M | 1 |
| Goto, C | 1 |
| Matsuura, N | 1 |
| Sakai, T | 1 |
| Wakabayashi, K | 1 |
| Neugut, AI | 2 |
| Reimers, MS | 3 |
| Bastiaannet, E | 4 |
| Langley, RE | 1 |
| van Eijk, R | 2 |
| van Vlierberghe, RL | 1 |
| Lemmens, VE | 3 |
| van Herk-Sukel, MP | 4 |
| van Wezel, T | 2 |
| Fodde, R | 2 |
| Kuppen, PJ | 2 |
| Morreau, H | 2 |
| van de Velde, CJ | 4 |
| Liefers, GJ | 4 |
| Kmietowicz, Z | 2 |
| Sung, JJ | 1 |
| Wołosik, K | 1 |
| Markowska, A | 1 |
| Kuźmicz, I | 1 |
| Osman, NH | 1 |
| Said, UZ | 1 |
| El-Waseef, AM | 1 |
| Ahmed, ES | 1 |
| Ng, K | 2 |
| Meyerhardt, JA | 1 |
| Sato, K | 1 |
| Chan, JA | 1 |
| Niedzwiecki, D | 1 |
| Saltz, LB | 1 |
| Mayer, RJ | 1 |
| Benson, AB | 1 |
| Schaefer, PL | 1 |
| Whittom, R | 1 |
| Hantel, A | 1 |
| Goldberg, RM | 1 |
| Venook, AP | 1 |
| Ogino, S | 1 |
| Giovannucci, EL | 2 |
| Fuchs, CS | 3 |
| Dawson, DM | 1 |
| Kresak, A | 1 |
| Lawrence, EG | 1 |
| Yang, P | 1 |
| Chen, Y | 1 |
| Willis, JE | 1 |
| Kopelovich, L | 6 |
| Lee, M | 5 |
| Gibbs, P | 2 |
| Wang, X | 2 |
| Diao, Y | 1 |
| Liu, Y | 4 |
| Gao, N | 1 |
| Gao, D | 1 |
| Wan, Y | 1 |
| Zhong, J | 1 |
| Jin, G | 1 |
| Nelson, N | 1 |
| Roy, HK | 1 |
| Turzhitsky, V | 1 |
| Wali, R | 1 |
| Radosevich, AJ | 1 |
| Jovanovic, B | 1 |
| Della'Zanna, G | 1 |
| Umar, A | 1 |
| Rubin, DT | 1 |
| Goldberg, MJ | 1 |
| Bianchi, L | 1 |
| De La Cruz, M | 1 |
| Bogojevic, A | 1 |
| Helenowski, IB | 1 |
| Rodriguez, L | 1 |
| Chatterton, R | 1 |
| Skripkauskas, S | 1 |
| Page, K | 1 |
| Weber, CR | 1 |
| Huang, X | 1 |
| Richmond, E | 1 |
| Bergan, RC | 1 |
| Backman, V | 1 |
| Wang, Y | 1 |
| Du, C | 1 |
| Zhao, M | 1 |
| Li, M | 1 |
| Zhang, N | 1 |
| Wang, J | 3 |
| Luo, F | 1 |
| Serebruany, VL | 3 |
| Cherepanov, V | 1 |
| Cabrera-Fuentes, HA | 1 |
| Kim, MH | 1 |
| Ai, G | 1 |
| Dachineni, R | 1 |
| Kumar, DR | 1 |
| Marimuthu, S | 2 |
| Alfonso, LF | 2 |
| Bhat, GJ | 2 |
| Li, YF | 1 |
| Gao, WQ | 1 |
| Li, YX | 1 |
| Feng, QZ | 1 |
| Zhu, P | 1 |
| Aoki, T | 1 |
| Ricciardiello, L | 2 |
| Ahnen, DJ | 2 |
| Lynch, PM | 2 |
| Guo, Y | 3 |
| Zhang, C | 2 |
| Su, ZY | 2 |
| Li, W | 1 |
| Huang, MT | 2 |
| Kong, AN | 3 |
| Voora, D | 1 |
| Rao, AK | 1 |
| Jalagadugula, GS | 1 |
| Myers, R | 1 |
| Harris, E | 1 |
| Ortel, TL | 1 |
| Ginsburg, GS | 1 |
| Vaughan, LE | 1 |
| Prizment, A | 1 |
| Blair, CK | 1 |
| Thomas, W | 1 |
| Anderson, KE | 2 |
| Murphy, C | 1 |
| Turner, N | 1 |
| Wong, HL | 1 |
| Sinnathamby, M | 1 |
| Tie, J | 1 |
| Lee, B | 1 |
| Desai, J | 1 |
| Skinner, I | 1 |
| Christie, M | 1 |
| Hutchinson, R | 1 |
| Lunke, S | 1 |
| Waring, P | 1 |
| Tran, B | 1 |
| Mitrugno, A | 1 |
| Sylman, JL | 1 |
| Ngo, AT | 1 |
| Pang, J | 1 |
| Sears, RC | 1 |
| Williams, CD | 1 |
| McCarty, OJ | 1 |
| Lichtenberger, LM | 2 |
| Fang, D | 1 |
| Bick, RJ | 1 |
| Poindexter, BJ | 1 |
| Phan, T | 1 |
| Bergeron, AL | 1 |
| Pradhan, S | 1 |
| Dial, EJ | 2 |
| Vijayan, KV | 1 |
| Zhu, Y | 1 |
| Wang, F | 1 |
| Zhao, Y | 2 |
| Wang, P | 1 |
| Sang, S | 1 |
| Frouws, MA | 1 |
| Swets, M | 1 |
| Prinse, B | 1 |
| Shaukat, A | 1 |
| Gaspar, JM | 1 |
| Wang, R | 1 |
| Hart, RP | 1 |
| Verzi, MP | 1 |
| Ouyang, N | 6 |
| Williams, JL | 7 |
| Rigas, B | 19 |
| Sandler, RS | 2 |
| Lai, MY | 1 |
| Huang, JA | 3 |
| Liang, ZH | 1 |
| Jiang, HX | 1 |
| Tang, GD | 1 |
| Ju, J | 1 |
| Xiao, H | 1 |
| Simi, B | 2 |
| Hao, X | 1 |
| Reddy, BS | 5 |
| Newmark, H | 1 |
| Yang, CS | 1 |
| Slattery, ML | 11 |
| Wolff, RK | 7 |
| Curtin, K | 3 |
| Fitzpatrick, F | 1 |
| Herrick, J | 3 |
| Caan, BJ | 4 |
| Samowitz, WS | 2 |
| Wysota, BA | 1 |
| Gorard, DA | 1 |
| Breslow, RG | 1 |
| Caiado, J | 1 |
| Castells, MC | 1 |
| Elwood, PC | 1 |
| Gallagher, AM | 1 |
| Duthie, GG | 1 |
| Mur, LA | 1 |
| Morgan, G | 2 |
| Marshall, JR | 2 |
| Hua, A | 1 |
| Mackenzie, GG | 1 |
| Bousserouel, S | 1 |
| Gosse, F | 2 |
| Bouhadjar, M | 2 |
| Soler, L | 2 |
| Marescaux, J | 2 |
| Raul, F | 2 |
| Sawhney, MS | 1 |
| McDougall, H | 1 |
| Nelson, DB | 1 |
| Bond, JH | 1 |
| Zhang, Z | 3 |
| Huang, L | 1 |
| Zhao, W | 1 |
| McCarthy, DM | 1 |
| Kanthamneni, N | 1 |
| Chaudhary, A | 2 |
| Prabhu, S | 2 |
| Rufner, KL | 1 |
| Park, MK | 1 |
| Tweed, EM | 1 |
| Metz, J | 1 |
| Chattopadhyay, M | 3 |
| Goswami, S | 2 |
| Rodes, DB | 1 |
| Kodela, R | 3 |
| Velazquez, CA | 1 |
| Boring, D | 1 |
| Crowell, JA | 2 |
| Kashfi, K | 10 |
| Rothwell, PM | 1 |
| Wilson, M | 1 |
| Elwin, CE | 1 |
| Norrving, B | 1 |
| Algra, A | 1 |
| Warlow, CP | 1 |
| Meade, TW | 1 |
| Heijink, DM | 1 |
| Jalving, M | 1 |
| Oosterhuis, D | 1 |
| Sloots, IA | 1 |
| Koster, R | 1 |
| Hollema, H | 2 |
| Kleibeuker, JH | 2 |
| Koornstra, JJ | 1 |
| de Vries, EG | 2 |
| de Jong, S | 2 |
| Greenspan, EJ | 1 |
| Madigan, JP | 1 |
| Boardman, LA | 1 |
| Rosenberg, DW | 1 |
| Robb-Nicholson, C | 1 |
| Ji, P | 1 |
| Gravitz, L | 1 |
| Metz, AJ | 1 |
| Bourke, MJ | 1 |
| Moss, A | 1 |
| Williams, SJ | 1 |
| Swan, MP | 1 |
| Byth, K | 1 |
| Kawaratani, Y | 1 |
| Harada, T | 1 |
| Hirata, Y | 1 |
| Nagaoka, Y | 1 |
| Tanimura, S | 1 |
| Shibano, M | 1 |
| Taniguchi, M | 1 |
| Yasuda, M | 1 |
| Baba, K | 1 |
| Uesato, S | 1 |
| Zhang, X | 1 |
| Smith-Warner, SA | 1 |
| Wu, K | 1 |
| Spiegelman, D | 1 |
| Willett, WC | 2 |
| Chivukula, RS | 1 |
| Moridani, M | 1 |
| Hagen, FK | 1 |
| Sutaria, D | 1 |
| Huang, Y | 1 |
| Femia, AP | 1 |
| Salvianti, F | 1 |
| Luceri, C | 1 |
| Dolara, P | 1 |
| Salvadori, M | 1 |
| Pinzani, P | 1 |
| Caderni, G | 1 |
| Maxwell, PH | 1 |
| Olson, KR | 1 |
| Sampieri, K | 1 |
| Dekkers, OM | 1 |
| de Craen, AJ | 2 |
| Lemmens, V | 1 |
| van den Broek, CB | 2 |
| Coebergh, JW | 1 |
| Herings, RM | 1 |
| Lundgreen, A | 3 |
| Welbourn, B | 2 |
| Corcoran, C | 2 |
| Lanas, A | 1 |
| Bondurant, KL | 1 |
| Herrick, JS | 2 |
| Kadlubar, S | 1 |
| Rahman, M | 1 |
| Selvarajan, K | 1 |
| Hasan, MR | 1 |
| Chan, AP | 1 |
| Jin, C | 1 |
| Kim, J | 1 |
| Chan, SK | 1 |
| Le, ND | 1 |
| Kim, YB | 1 |
| Tai, IT | 1 |
| Pathi, S | 1 |
| Jutooru, I | 1 |
| Chadalapaka, G | 1 |
| Nair, V | 1 |
| Lee, SO | 1 |
| Safe, S | 1 |
| Pennarun, B | 1 |
| Boersma-van Ek, W | 1 |
| Kruyt, FA | 1 |
| Gan, ZY | 1 |
| Rao, PP | 1 |
| Nia, KV | 1 |
| Velázquez-Martínez, CA | 1 |
| Dinicolantonio, JJ | 1 |
| Can, MM | 1 |
| Goto, S | 1 |
| Juarranz, M | 1 |
| Calle-Purón, ME | 1 |
| González-Navarro, A | 1 |
| Regidor-Poyatos, E | 1 |
| Soriano, T | 1 |
| Martínez-Hernandez, D | 1 |
| Rojas, VD | 1 |
| Guinee, VF | 1 |
| Vainio, H | 1 |
| Elwood, P | 1 |
| Göke, MN | 1 |
| Yu, HG | 2 |
| Yang, YN | 2 |
| Huang, H | 1 |
| Luo, HS | 2 |
| Yu, JP | 2 |
| Meier, JJ | 2 |
| Schrader, H | 2 |
| Bastian, A | 2 |
| Schmidt, WE | 2 |
| Schmitz, F | 2 |
| Simon, HB | 1 |
| Goel, A | 1 |
| Chang, DK | 1 |
| Gasche, C | 2 |
| Boland, CR | 1 |
| Wong, BC | 2 |
| Jiang, Xh | 1 |
| Fan, XM | 1 |
| Lin, MC | 2 |
| Jiang, SH | 1 |
| Lam, SK | 2 |
| Kung, HF | 2 |
| Fischman, J | 1 |
| Brown, JR | 2 |
| Seed, MP | 2 |
| Willoughby, DA | 2 |
| Tesei, A | 3 |
| Ricotti, L | 1 |
| Ulivi, P | 3 |
| Medri, L | 3 |
| Amadori, D | 3 |
| Zoli, W | 3 |
| Terdiman, JP | 1 |
| Mathers, JC | 1 |
| Mickleburgh, I | 1 |
| Chapman, PC | 1 |
| Bishop, DT | 1 |
| Burn, J | 1 |
| Eklou-Kalonji, E | 1 |
| Andriamihaja, M | 1 |
| Reinaud, P | 1 |
| Mayeur, C | 1 |
| Camous, S | 1 |
| Robert, V | 1 |
| Charpigny, G | 1 |
| Blachier, F | 1 |
| Germann, A | 1 |
| Dihlmann, S | 1 |
| Hergenhahn, M | 1 |
| Doeberitz, Mv | 1 |
| Koesters, R | 1 |
| Martinez, ME | 1 |
| O'Brien, TG | 1 |
| Fultz, KE | 1 |
| Babbar, N | 2 |
| Yerushalmi, H | 1 |
| Qu, N | 1 |
| Boorman, D | 1 |
| Einspahr, J | 1 |
| Alberts, DS | 2 |
| Gerner, EW | 3 |
| Ouyang, Q | 3 |
| Gan, H | 2 |
| Lotufo, PA | 1 |
| Escribano, M | 1 |
| Molero, L | 1 |
| López-Farré, A | 1 |
| Abarrategui, C | 1 |
| Carrasco, C | 1 |
| García-Mendez, A | 1 |
| Manzarbeitia, F | 1 |
| Martín, MJ | 1 |
| Vázquez, M | 1 |
| Sánchez-Fayos, P | 1 |
| Rico, L | 1 |
| Porres Cubero, JC | 1 |
| Shtivelband, MI | 1 |
| Juneja, HS | 1 |
| Lee, S | 1 |
| Wu, KK | 2 |
| Nath, N | 2 |
| Chen, J | 4 |
| Di Napoli, M | 1 |
| Papa, F | 1 |
| Hundley, TR | 3 |
| Gao, J | 5 |
| del Soldato, P | 3 |
| Hardwick, JC | 1 |
| van Santen, M | 1 |
| van den Brink, GR | 1 |
| van Deventer, SJ | 1 |
| Peppelenbosch, MP | 2 |
| Montalto, M | 1 |
| Maggiano, N | 1 |
| Ricci, R | 1 |
| Curigliano, V | 1 |
| Santoro, L | 1 |
| Di Nicuolo, F | 1 |
| Vecchio, FM | 1 |
| Gasbarrini, A | 1 |
| Gasbarrini, G | 1 |
| Borgo, S | 2 |
| Glekas, A | 1 |
| Benedini, F | 1 |
| Noguera Aguilar, JF | 2 |
| Plaza Martínez, A | 2 |
| Amengual Antich, I | 2 |
| Morón Canis, JM | 1 |
| Tortajada Collado, C | 2 |
| Pujol Tugores, JJ | 2 |
| Kim, SJ | 1 |
| Turner, S | 1 |
| Killion, S | 1 |
| Hellerstein, MK | 1 |
| Ashktorab, H | 1 |
| Dawkins, FW | 1 |
| Mohamed, R | 1 |
| Larbi, D | 1 |
| Smoot, DT | 1 |
| Doyen, JR | 1 |
| Corpet, DE | 1 |
| Pierre, F | 1 |
| Spiegel, A | 1 |
| Liu, X | 4 |
| Go, MF | 1 |
| Tsioulias, GJ | 2 |
| Hayasaka, E | 1 |
| Kim, KM | 1 |
| Song, JJ | 1 |
| An, JY | 1 |
| Kwon, YT | 1 |
| Lee, YJ | 1 |
| Casero, RA | 1 |
| Ibarra de la Rosa, J | 1 |
| Gamundí Gamundí, A | 1 |
| Shin, SJ | 1 |
| Kim, BC | 1 |
| Park, S | 1 |
| Kim, S | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
| Paik, CH | 1 |
| Han, DS | 1 |
| Ignatenko, NA | 1 |
| Lance, P | 1 |
| Hurley, LH | 1 |
| Paterson, J | 1 |
| Baxter, G | 1 |
| Lawrence, J | 1 |
| Duthie, G | 1 |
| He, H | 1 |
| Xia, HH | 1 |
| Wang, JD | 1 |
| Gu, Q | 1 |
| Zou, B | 1 |
| Chan, AO | 1 |
| Yuen, MF | 1 |
| Wolff, R | 2 |
| Ma, KN | 4 |
| Sweeney, C | 2 |
| Murtaugh, M | 1 |
| Levin, TR | 2 |
| Samowitz, W | 1 |
| Sansbury, LB | 1 |
| Millikan, RC | 1 |
| Schroeder, JC | 1 |
| North, KE | 1 |
| Moorman, PG | 1 |
| Keku, TO | 1 |
| de Cotret, AR | 1 |
| Player, J | 1 |
| Wang, CX | 2 |
| Khor, TO | 1 |
| Zheng, X | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| Zupi, G | 1 |
| Fabbri, F | 2 |
| Rosetti, M | 2 |
| Cecconetto, L | 1 |
| Bolla, M | 2 |
| Terhaar Sive Droste, JS | 1 |
| Tuynman, JB | 2 |
| Van Dullemen, HM | 1 |
| Mulder, CJ | 1 |
| Andersen, K | 1 |
| Patlolla, JM | 1 |
| Yin, H | 1 |
| Yang, W | 1 |
| Cheng, J | 1 |
| Zhou, Y | 1 |
| Jamaluddin, MS | 1 |
| Wang, CH | 1 |
| Tang, CW | 1 |
| Huang, MH | 1 |
| Li, X | 1 |
| Mahipal, A | 1 |
| Limburg, PJ | 1 |
| Folsom, AR | 2 |
| Lewis, JD | 1 |
| Schinnar, R | 1 |
| Bilker, WB | 1 |
| Strom, BL | 1 |
| Levine, JS | 1 |
| Luciani, MG | 1 |
| Campregher, C | 1 |
| Osswald, AB | 1 |
| Foltzer-Jourdainne, C | 1 |
| Vannini, I | 1 |
| Vermeulen, L | 1 |
| Boon, EM | 1 |
| Kemper, K | 1 |
| Zwinderman, AH | 1 |
| Richel, DJ | 1 |
| Accioly, MT | 1 |
| Pacheco, P | 1 |
| Maya-Monteiro, CM | 1 |
| Carrossini, N | 1 |
| Robbs, BK | 1 |
| Oliveira, SS | 1 |
| Kaufmann, C | 1 |
| Morgado-Diaz, JA | 1 |
| Bozza, PT | 1 |
| Viola, JP | 1 |
| Hellwig, JP | 1 |
| Lipton, A | 1 |
| Scialla, S | 1 |
| Harvey, H | 1 |
| Dixon, R | 1 |
| Gordon, R | 1 |
| Hamilton, R | 1 |
| Ramsey, H | 1 |
| Weltz, M | 1 |
| Heckard, R | 1 |
| White, D | 1 |
| Doubilet, P | 1 |
| Donowitz, M | 1 |
| Pauker, SG | 1 |
| Doran, J | 1 |
| Hardcastle, JD | 2 |
| Kelloff, GJ | 2 |
| Boone, CW | 1 |
| Greenwald, P | 1 |
| Covey, JM | 1 |
| Doody, LA | 1 |
| Knapp, GG | 1 |
| Giovannucci, E | 1 |
| Egan, KM | 1 |
| Hunter, DJ | 1 |
| Stampfer, MJ | 1 |
| Colditz, GA | 1 |
| Speizer, FE | 1 |
| Marshall, KG | 1 |
| Arvind, P | 1 |
| Papavassiliou, ED | 1 |
| Qiao, L | 2 |
| Lovelace, CI | 1 |
| Duceman, B | 1 |
| Pence, BC | 1 |
| Dunn, DM | 1 |
| Zhao, C | 1 |
| Landers, M | 1 |
| Wargovich, MJ | 2 |
| Nelson, C | 1 |
| Chen, CD | 1 |
| Harris, C | 1 |
| Yang, E | 1 |
| Velasco, M | 1 |
| Sweeting, JG | 1 |
| Morgan, GP | 3 |
| Müller, AD | 1 |
| Sonnenberg, A | 1 |
| Wasserman, IH | 1 |
| Davis, AE | 1 |
| Patterson, F | 1 |
| Sauer, R | 1 |
| Mereto, E | 1 |
| Frencia, L | 1 |
| Ghia, M | 1 |
| Helzlsouer, KJ | 1 |
| Block, G | 1 |
| Blumberg, J | 1 |
| Diplock, AT | 1 |
| Levine, M | 1 |
| Schulplein, RJ | 1 |
| Spence, JT | 1 |
| Simic, MG | 1 |
| Adami, HO | 1 |
| Williams, JG | 2 |
| Goldman, IS | 1 |
| Levine, L | 1 |
| Farmer, KC | 1 |
| Goulston, K | 1 |
| Macrae, F | 1 |
| Smigel, K | 1 |
| Suh, O | 1 |
| Mettlin, C | 1 |
| Petrelli, NJ | 1 |
| Rivenson, A | 1 |
| Kelloff, G | 1 |
| Paganini-Hill, A | 3 |
| Logan, RF | 1 |
| Little, J | 2 |
| Hawtin, PG | 1 |
| Thun, MJ | 4 |
| Namboodiri, MM | 2 |
| Calle, EE | 1 |
| Flanders, WD | 1 |
| Heath, CW | 2 |
| Kelly, R | 1 |
| Greenberg, ER | 2 |
| Freeman, DH | 1 |
| Mandel, JS | 1 |
| Haile, R | 1 |
| Odeh, M | 1 |
| Yokoyama, I | 1 |
| Hayashi, S | 1 |
| Kobayashi, T | 1 |
| Negita, M | 1 |
| Yasutomi, M | 1 |
| Uchida, K | 1 |
| Takagi, H | 1 |
| Shiff, SJ | 1 |
| Koutsos, MI | 1 |
| Kanamori, S | 1 |
| Sugiyama, S | 1 |
| Goto, H | 1 |
| Hayakawa, T | 1 |
| Shimomura, Y | 1 |
| Ozawa, T | 1 |
| Goldberg, Y | 1 |
| DuBois, RN | 2 |
| Shao, J | 2 |
| Tsujii, M | 1 |
| Sheng, H | 1 |
| Beauchamp, RD | 1 |
| Marks, RD | 1 |
| Iigo, M | 1 |
| Nakagawa, T | 1 |
| Ishikawa, C | 1 |
| Iwahori, Y | 1 |
| Asamoto, M | 1 |
| Yazawa, K | 1 |
| Araki, E | 1 |
| Tsuda, H | 1 |
| Barnes, CJ | 4 |
| Hardman, WE | 3 |
| Cameron, IL | 3 |
| Benamouzig, R | 1 |
| Chaussade, S | 1 |
| Munoz, N | 1 |
| Rautureau, J | 1 |
| Couturier, D | 1 |
| Schatzkin, A | 1 |
| Lanza, E | 1 |
| Freedman, LS | 1 |
| Tangrea, J | 1 |
| Cooper, MR | 1 |
| Murphy, PA | 1 |
| Selby, JV | 1 |
| Shike, M | 1 |
| Schade, RR | 1 |
| Burt, RW | 1 |
| Kikendall, JW | 1 |
| Cahill, J | 1 |
| Schaffer, D | 2 |
| Edwards, SL | 1 |
| Gustafson-Svärd, C | 1 |
| Lilja, I | 1 |
| Hallböök, O | 1 |
| Sjödahl, R | 1 |
| Featherstone, C | 1 |
| Ricchi, P | 1 |
| Pignata, S | 1 |
| Di Popolo, A | 1 |
| Memoli, A | 1 |
| Apicella, A | 1 |
| Zarrilli, R | 1 |
| Acquaviva, AM | 1 |
| Sönksen, P | 1 |
| Jacobs, H | 1 |
| Orme, S | 1 |
| Belchetz, P | 1 |
| Freemantle, CN | 1 |
| Alam, CA | 1 |
| Colville-Nash, PR | 1 |
| Papworth, JL | 1 |
| Somerville, KW | 1 |
| Krishnan, K | 1 |
| Ruffin, MT | 1 |
| Brenner, DE | 1 |
| Rowlinson, SW | 1 |
| Garner, C | 1 |
| Seibert, K | 1 |
| Gupta, RA | 1 |
| Bak, AW | 1 |
| McKnight, W | 1 |
| Li, P | 1 |
| Calignano, A | 1 |
| Cirino, G | 1 |
| Wallace, JL | 1 |
| Rosenberg, L | 1 |
| Louik, C | 1 |
| Shapiro, S | 1 |
| Bours, V | 1 |
| Jerusalem, G | 1 |
| Fillet, G | 1 |
| Subbegowda, R | 1 |
| Frommel, TO | 2 |
| Van Lieshout, EM | 1 |
| Tiemessen, DM | 1 |
| Roelofs, HM | 1 |
| Peters, WH | 1 |
| Boone, WT | 1 |
| Newmark, HL | 1 |
| Bertagnolli, MM | 1 |
| Rosenberg, DJ | 1 |
| Ahsan, H | 1 |
| Jacobson, JS | 1 |
| Wahid, N | 1 |
| Hagan, M | 1 |
| Rahman, MI | 1 |
| Khan, ZR | 1 |
| Chen, L | 1 |
| Pablos-Mendez, A | 1 |
| Shea, S | 1 |
| Shpitz, B | 1 |
| Bomstein, Y | 1 |
| Kariv, N | 1 |
| Shalev, M | 1 |
| Buklan, G | 1 |
| Bernheim, J | 1 |
| Dyavanapalli, M | 1 |
| Oldham, T | 1 |
| Kazi, N | 1 |
| Lietz, H | 1 |
| Liao, Y | 1 |
| Mobarhan, S | 1 |
| Schwenger, P | 1 |
| Alpert, D | 1 |
| Skolnik, EY | 1 |
| Vilcek, J | 1 |
| Li, H | 1 |
| Schut, HA | 1 |
| Conran, P | 1 |
| Kramer, PM | 1 |
| Hawk, EE | 1 |
| Pereira, MA | 1 |
| Hamby-Mason, RL | 1 |
| Speeg, KV | 1 |
| Fujiwara, T | 1 |
| Kadowaki, Y | 1 |
| Fukazawa, T | 1 |
| Waku, T | 1 |
| Itoshima, T | 1 |
| Yamatsuji, T | 1 |
| Nishizaki, M | 1 |
| Roth, JA | 1 |
| Tanaka, N | 1 |
| Arber, N | 1 |
| Cook, NR | 1 |
| Le, IM | 1 |
| Manson, JE | 1 |
| Buring, JE | 1 |
| Hennekens, CH | 1 |
| Akashi, H | 2 |
| Han, HJ | 1 |
| Iizaka, M | 2 |
| Nakamura, Y | 2 |
| Allgayer, H | 1 |
| Tillmann, T | 1 |
| Hombach, A | 1 |
| Kruis, W | 1 |
| Pohl, C | 1 |
| Hasan, I | 1 |
| Castillo, E | 1 |
| Traganos, F | 1 |
| Bigler, J | 1 |
| Whitton, J | 1 |
| Fosdick, L | 1 |
| Bostick, RM | 1 |
| Stark, LA | 1 |
| Din, FV | 1 |
| Zwacka, RM | 1 |
| Dunlop, MG | 1 |
| Weiss, H | 1 |
| Amberger, A | 1 |
| Widschwendter, M | 1 |
| Margreiter, R | 1 |
| Ofner, D | 1 |
| Dietl, P | 1 |
| Bing, RJ | 1 |
| Narumiya, S | 1 |
| FitzGerald, GA | 1 |
| Benson, J | 1 |
| Furukawa, Y | 1 |
| Tsunoda, T | 1 |
| Ogawa, M | 1 |
| Ota, S | 1 |
| Bamba, H | 1 |
| Imai, Y | 1 |
| Arai, S | 1 |
| Fujiwara, K | 1 |
| Laufer, I | 1 |
| Thornley, GD | 1 |
| Stolberg, H | 1 |
| Craven, PA | 1 |
| DeRubertis, FR | 1 |
| Ducreux, M | 1 |
| Deutsch, ME | 1 |
| Travers, JD | 1 |
| Temple, AR | 1 |
| Gates, TN | 1 |
| Hsu, G | 2 |
| Ross, RK | 2 |
| Henderson, BE | 2 |
| Nightingale, SL | 1 |
| Welch, CE | 1 |
| Hedberg, S | 1 |
| Moertel, CG | 1 |
| Ahmann, DL | 1 |
| Taylor, WF | 1 |
| Schwartau, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia[NCT00468910] | Phase 2 | 79 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| Prevention of Females Malignancies in Families With Hereditary Breast Cancer by Personalized Optimization of Se Levels in the Organism.[NCT04014283] | 7,000 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| The Yield and Safety of Screening and Surveillance Colonoscopy in Elderly Patients (> 80 Years)[NCT00590434] | 169 participants (Actual) | Observational | 2006-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Spectral marker assessment was performed via LEBS analysis (low-coherence enhanced backscattering spectroscopy) on the uninvolved mucosal biopsies of subjects taken at baseline and after 3 months of treatment with either aspirin or placebo. FRAC characterizes the spatial autocorrelation function of mass density distribution in tissue.~SPEC and FRAC provide a measure of the fundamental characteristics of the tissue nanoscale architecture" (NCT00468910)
Timeframe: 3 months from baseline colonoscopy to end of intervention.
| Intervention | unitless (Mean) | |
|---|---|---|
| Baseline | Post Intervention | |
| Acetylsalicylic Acid | 142.41 | -407.78 |
| Placebo | 23.28 | 650.97 |
"Spectral marker assessment was performed via LEBS analysis (low-coherence enhanced backscattering spectroscopy) on the uninvolved mucosal biopsies of subjects taken at baseline and after 3 months of treatment with either aspirin or placebo. SPEC characterizes the size distribution of macromolecular complexes and other intracellular structures, with a decrease of the spectral slope implying a shift of the size distribution of intracellular structures toward smaller sizes.~Spectral markers SPEC and FRAC provide a measure of the fundamental characteristics of the tissue nanoscale architecture." (NCT00468910)
Timeframe: 3 months from baseline colonoscopy to end of intervention.
| Intervention | micron^-1 (Mean) | |
|---|---|---|
| Baseline | Post Intervention | |
| Acetylsalicylic Acid | 40.72 | 43.45 |
| Placebo | 37.54 | 37.52 |
Evaluate the effect of aspirin on colonic epithelial apoptosis and cell proliferation as assessed by immunohistochemical detection of Ki-67. These were performed on samples that had been previously analyzed for 4D-ELF. (NCT00468910)
Timeframe: 3 months from baseline colonoscopy to end of intervention.
| Intervention | Percentage of Total Cells (Mean) | |
|---|---|---|
| Baseline | 3 Months Intervention | |
| Acetylsalicylic Acid | 38.07 | 43.60 |
| Placebo | 40.45 | 37.74 |
Evaluate the effect of aspirin on colonic epithelial apoptosis and cell proliferation as assessed by immunohistochemical detection of cleaved caspase 3 .These were performed on samples that had been previously analyzed for 4D-ELF. (NCT00468910)
Timeframe: 3 months from baseline colonoscopy to end of intervention.
| Intervention | Percentage of Total Cells (Mean) | |
|---|---|---|
| Baseline | At 3 Months | |
| Acetylsalicylic Acid | 4.56 | 4.26 |
| Placebo | 5.24 | 7.26 |
Evaluate the effect of aspirin on platelet COX activity as measured by a peroxidase-based Cox enzyme activity assay. (NCT00468910)
Timeframe: 3 months from baseline colonoscopy to end of intervention.
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Baseline | Post Intervention | |
| Acetylsalicylic Acid | 712976.73 | 6914.87 |
| Placebo | 430109.56 | 200233.5 |
Evaluate the effect of aspirin on rectal prostaglandin levels. (NCT00468910)
Timeframe: 3 months from baseline colonoscopy to end of intervention.
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Baseline | Post Intervention | |
| Acetylsalicylic Acid | 305.93 | 211.97 |
| Placebo | 654.64 | 209.02 |
38 reviews available for aspirin and Cancer of Colon
| Article | Year |
|---|---|
Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Humans; Prospective Studies; Ri | 2021 |
[Aspirin and colorectal cancer].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Class I Phosphat | 2018 |
Could Aspirin and Diets High in Fiber Act Synergistically to Reduce the Risk of Colon Cancer in Humans?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Clinical Trials as Topic; Colonic | 2018 |
[Lunasin--a novel chemopreventive peptide].
Topics: Antineoplastic Agents; Antioxidants; Aspirin; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line | 2014 |
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopid | 2015 |
Chemoprevention of hereditary colon cancers: time for new strategies.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy P | 2016 |
Point/Counterpoint: Aspirin should not be promoted for colon cancer prevention: counterpoint.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Contraindications; Humans; Risk | 2008 |
Aspirin, salicylates, and cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Breast Neoplasms; Case-Control | 2009 |
Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
Topics: Animals; Aspirin; Clopidogrel; Colonic Neoplasms; Gastrointestinal Hemorrhage; Humans; Piperazines; | 2009 |
Nutrition and colon cancer prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Diet; | 2009 |
Clinical inquiries. Is aspirin effective for primary prevention of colon cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; | 2010 |
The public health potential of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Female | 2002 |
Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Aspirin; Colonic Neoplasms; Colorect | 2003 |
NCX-4016 NicOx.
Topics: Animals; Aspirin; Cardiovascular Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2003 |
Molecular targets of nitric-oxide-donating aspirin in cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cell Division; C | 2005 |
How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men.
Topics: Animals; Aspirin; beta Carotene; Calcium; Carcinogens; Colonic Neoplasms; Dietary Fiber; Humans; Mic | 2005 |
A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; Aspirin; Base Sequence; Colonic Neoplasms | 2005 |
Is there a role for dietary salicylates in health?
Topics: Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Fruit; Humans; Salicylic Acid; Vegetables | 2006 |
Chemoprevention for colon cancer: new opportunities, fact or fiction?
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplas | 2006 |
Clinical practice. Adenomatous polyps of the colon.
Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Co | 2006 |
Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Colon; Colonic Neoplasms; Cycloo | 1995 |
Summary of the round table discussion on strategies for cancer prevention: diet, food, additives, supplements, and drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Ascorbic Acid; Aspirin; Colonic Ne | 1994 |
Selections from current literature: using aspirin for primary or secondary prevention.
Topics: Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Humans; Primary Prevention | 1993 |
[Aspirin, non-steroidal anti-inflammatory agents and colonic carcinogenesis].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; | 1997 |
NSAID use and decreased risk of gastrointestinal cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Disease Models, Animal | 1996 |
Cyclo-oxygenase and colon cancer: clues to the aspirin effect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinogens; Colonic Neoplasms; Cyclooxygenase Inh | 1997 |
Aspirin and gastrointestinal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinoge | 1997 |
Chemoprevention of colon cancer by dietary administration of naturally-occurring and related synthetic agents.
Topics: Allyl Compounds; Anethole Trithione; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinoge | 1997 |
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Topics: Animals; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic N | 1997 |
Aspirin, NSAIDS, and colon cancer prevention: mechanisms?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase 2; Dise | 1998 |
Aspirin and its friends: an old standby with new prospects.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Colo | 1999 |
Do NSAIDs prevent colorectal cancer?
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neopl | 2000 |
Myocardial ischemia and infarction: growth of ideas.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2001 |
Genetic and pharmacological analysis of prostanoid receptor function.
Topics: Animals; Aspirin; Biological Transport; Bone Resorption; Cell Nucleus; Colonic Neoplasms; Cyclooxyge | 2001 |
[Colon cancer and COX-2].
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neopl | 2002 |
Aspirin and the potential role of prostaglandins in colon cancer.
Topics: Animals; Aspirin; Colonic Neoplasms; Humans; Prostaglandins | 1992 |
[Prevention of colorectal cancer: what is the role of aspirin?].
Topics: Aspirin; Colonic Neoplasms; Female; Humans; Male; Rectal Neoplasms | 1992 |
Gastrointestinal hemorrhage. I. General considerations of diagnosis and the rapy.
Topics: Anus Diseases; Aspirin; Biliary Tract Diseases; Blood Coagulation Disorders; Burns; Child; Child, Pr | 1973 |
12 trials available for aspirin and Cancer of Colon
| Article | Year |
|---|---|
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Class I Phosphatidylinositol 3-Kinases; Col | 2018 |
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Alcohol Drinking; Anticarcinogenic Agents; Aspirin; Colonic Ne | 2014 |
Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Chemoprevention; Colonic | 2017 |
Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization.
Topics: Acetates; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agent | 2009 |
Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Con | 2002 |
Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer.
Topics: Actuarial Analysis; Adjuvants, Pharmaceutic; Aspirin; Blood Platelets; Colonic Neoplasms; Humans; Pa | 1982 |
Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme.
Topics: Acetaminophen; Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies | 1993 |
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics.
Topics: Adenoma; Adenomatous Polyps; Adult; Aspirin; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Demogra | 1996 |
Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon.
Topics: Adenomatous Polyps; Aspirin; Biomarkers; Biopsy, Needle; Colonic Neoplasms; Dinoprostone; Double-Bli | 1999 |
Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Co | 2000 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Aspirin; BCG Vaccine; Carcinoma in Situ; Clinical Trials as Topi | 1990 |
Aspirin and pancreatic cancer pain.
Topics: Adenocarcinoma; Aspirin; Carcinoma; Codeine; Colonic Neoplasms; Humans; Pancreatic Neoplasms; Placeb | 1971 |
230 other studies available for aspirin and Cancer of Colon
| Article | Year |
|---|---|
Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
Topics: Acetylation; Acetylene; Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 1998 |
Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Biological Assay; Breast Neoplasms; Cell L | 2012 |
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygen | 2013 |
Andean berry (Vaccinium meridionale Swartz) juice, in combination with Aspirin, displayed antiproliferative and pro-apoptotic mechanisms in vitro while exhibiting protective effects against AOM-induced colorectal cancer in vivo.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Coloni | 2022 |
Targeting the Leukotriene Pathway for Colon Cancer Interception.
Topics: Aberrant Crypt Foci; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidon | 2022 |
Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells.
Topics: Animals; Aspirin; Azoxymethane; Carcinogenesis; Cell Transformation, Neoplastic; Colitis; Colonic Ne | 2023 |
Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azoxymethane; Ca | 2019 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Efficacy of Cangrelor as Bridging Therapy Post PCI.
Topics: Adenosine Monophosphate; Aged; Aspirin; Colectomy; Colonic Neoplasms; Drug-Eluting Stents; Factor Xa | 2020 |
Resveratrol and Resveratrol-Aspirin Hybrid Compounds as Potent Intestinal Anti-Inflammatory and Anti-Tumor Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Colonic Neoplasms; Enzyme Inhibit | 2020 |
Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging.
Topics: Aged; Aged, 80 and over; Aging; Aspirin; Case-Control Studies; Colon; Colonic Neoplasms; CpG Islands | 2020 |
Letter: synergistic role of gut flora with aspirin to prevent colorectal cancers-authors' reply.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Risk | 2020 |
Editorial: the microbiome, aspirin and colorectal cancer.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Microbiota | 2020 |
Letter: synergistic role of gut flora with aspirin to prevent colorectal cancers.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Risk | 2020 |
Editorial: the microbiome, aspirin and colorectal cancer-authors' reply.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Microbiota | 2020 |
New Formulation of a Methylseleno-Aspirin Analog with Anticancer Activity towards Colon Cancer.
Topics: Antineoplastic Agents; Aspirin; beta-Cyclodextrins; Cell Proliferation; Colonic Neoplasms; Drug Libe | 2020 |
Reply to M. Løberg et al.
Topics: Aspirin; Cause of Death; Colonic Neoplasms; Colorectal Neoplasms; Death; Humans | 2017 |
NSAIDs and Colorectal Cancer Phenotypes: What Now?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Humans; P | 2019 |
Expression of Metallothionein after Administration of Aspirin, Vitamin C or Zinc Supplement in the DMH Induced Colon Carcinoma in Rat
Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; Col | 2018 |
Do Aspirin and Clopidogrel Follow the Same Road Toward Prevention of Colorectal Cancer?
Topics: Aspirin; Clopidogrel; Colonic Neoplasms; Colorectal Neoplasms; Humans; Platelet Aggregation Inhibito | 2019 |
HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Che | 2019 |
Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; bcl-2-Associated X Prot | 2013 |
Aspirin may help colon cancer patients live longer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms, Hereditar | 2013 |
Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention.
Topics: Animals; Aspirin; Chemoprevention; Colon; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Fem | 2013 |
Aspirin use after diagnosis improves survival in older adults with colon cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Female; Humans; Male | 2013 |
Protective role of aspirin, vitamin C, and zinc and their effects on zinc status in the DMH-induced colon carcinoma model.
Topics: 1,2-Dimethylhydrazine; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antio | 2013 |
Aspirin as adjuvant therapy for stage III colon cancer: standard of care?
Topics: Aspirin; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Cyclooxygenas | 2014 |
Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.
Topics: Aspirin; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Cohort Studies; Colonic Neoplasm | 2014 |
Study finds that aspirin improves survival after colon cancer diagnosis.
Topics: Aspirin; Biomarkers, Tumor; Colonic Neoplasms; Cyclooxygenase 2; Female; Histocompatibility Antigens | 2014 |
Is aspirin for colorectal cancer prevention on the prime time yet?
Topics: Adenocarcinoma; Adenoma; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2014 |
Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Aspirin; Carcinoembryonic Ant | 2015 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemother | 2015 |
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carc | 2015 |
RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Co | 2015 |
Response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Co | 2015 |
Synergistic apoptosis-inducing effect of aspirin and isosorbide mononitrate on human colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Colonic Neoplasms; Drug Synergism; Female; HCT11 | 2015 |
On Trial: Evidence From Using Aspirin to Prevent Cancer.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Clinical Trials as | 2015 |
Treatment of colonic transplantation tumor-bearing mice with a high-dose aspirin in a short period of time.
Topics: Animals; Aspirin; Cell Line, Tumor; Colonic Neoplasms; Cost-Benefit Analysis; Dose-Response Relation | 2016 |
Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53.
Topics: Acetylation; Aspirin; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; Cyclin-Dependent Kinase Inh | 2016 |
Management of acute perioperative myocardial infarction: a case report of concomitant acute myocardial infarction and tumor bleeding in the transverse colon.
Topics: Aged; Aspirin; Colon, Transverse; Colonic Neoplasms; Colonoscopy; Coronary Angiography; Disease Mana | 2016 |
[Can an antagonist for prostaglandin receptor be an alternative of aspirin?].
Topics: Animals; Aspirin; Colonic Neoplasms; Humans; Receptors, Prostaglandin | 2016 |
The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Colitis; Colonic Neoplasms; Cyclooxygenase | 2016 |
Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Line, Tumor; Colonic Neoplasms; Core Binding | 2016 |
Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's Health Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; | 2016 |
Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Class I | 2017 |
Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC.
Topics: Aspirin; Blood Platelets; Carcinogenesis; Cell Communication; Cell Line, Tumor; Cell Proliferation; | 2017 |
Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1.
Topics: Animals; Aspirin; Blood Platelets; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxyge | 2017 |
Gastroprotective [6]-Gingerol Aspirinate as a Novel Chemopreventive Prodrug of Aspirin for Colon Cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Catechols; Cell Li | 2017 |
The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.
Topics: Aged; Aged, 80 and over; Aspirin; Colon; Colonic Neoplasms; Female; Gene Expression; Humans; Male; M | 2017 |
Another Go Around for Aspirin: The Gut Is the Heart of the Matter this Time.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neopl | 2017 |
Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq.
Topics: Animals; Aspirin; Colitis; Colonic Neoplasms; Curcumin; Drug Therapy, Combination; Gene Expression P | 2017 |
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; HT29 Cells; Humans; Im | 2008 |
Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480.
Topics: Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2008 |
Effects of combination of calcium and aspirin on azoxymethane-induced aberrant crypt foci formation in the colons of mice and rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azoxymethane; Calcium, Dietary; Carcinoge | 2008 |
Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransferase; Aspirin; Case-C | 2009 |
Colonic carcinoma unmasked by dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Colonic Neoplasms; Female; Gastrointestinal Hemorrhage; Humans; Incidental Fin | 2008 |
The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
Topics: Activating Transcription Factor 2; Antineoplastic Agents; Aspirin; Cell Cycle; Cell Proliferation; C | 2009 |
Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carc | 2010 |
Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Colonic Neoplas | 2010 |
Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.
Topics: Animals; Annexin A1; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Growth Proces | 2010 |
Aspirin as colon cancer treatment?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase 2; Humans; Survi | 2010 |
Probing the occult: testing for blood in the stools.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Colonic Neoplasms; Co | 2010 |
Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Calcium; Cell Line, Tumor; | 2010 |
In vitro anti-proliferative effects of the willow bark extract STW 33-I.
Topics: Apoptosis; Aspirin; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Diclofe | 2010 |
NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Caspase 3; Cell Prolif | 2010 |
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Colorectal Neoplasms; Follow-Up Studies; Humans | 2010 |
TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Asp | 2011 |
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Catenin; Blotting, West | 2011 |
By the way, doctor. I keep hearing that aspirin can help prevent colon cancer, but I have no idea how much I should take. Can you help? I've had adenomatous polyps in the past.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspiri | 2010 |
Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action.
Topics: Animals; Aspirin; beta Catenin; Colonic Neoplasms; Electrophoretic Mobility Shift Assay; Humans; Imm | 2011 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Factors that predict bleeding following endoscopic mucosal resection of large colonic lesions.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Colon, Ascending; Colonic Neoplasms; Colonosco | 2011 |
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
Topics: Acetates; Animals; Aspirin; Benzoates; Carbamates; Cell Division; Cell Line, Tumor; Colonic Neoplasm | 2011 |
Aspirin use, body mass index, physical activity, plasma C-peptide, and colon cancer risk in US health professionals.
Topics: Adult; Aged; Aspirin; Body Mass Index; C-Peptide; Case-Control Studies; Chi-Square Distribution; Col | 2011 |
Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets.
Topics: Acetylation; Aspirin; Colonic Neoplasms; Enzyme Activation; Glucosephosphate Dehydrogenase; Glycosyl | 2011 |
Chemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment system.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; As | 2011 |
Sustained proliferation and resistance to apoptosis after a cytotoxic insult are early alterations in rat colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Aspirin; bcl-2 Homologous Antagonist-Killer Protein; Biom | 2012 |
Tumor strengths and frailties: Aspiring to prevent colon cancer.
Topics: Aspirin; Cell Transformation, Neoplastic; Colonic Neoplasms; Colorectal Neoplasms, Hereditary Nonpol | 2012 |
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Proliferation; Colonic Neoplasm | 2012 |
Use of aspirin postdiagnosis improves survival for colon cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; | 2012 |
Oxidative balance and colon and rectal cancer: interaction of lifestyle factors and genes.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Diet; Female; Gene | 2012 |
Study finds possible role for aspirin as treatment for colon cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Drug Repositioning; Humans; Off | 2012 |
Aspirin: the balance between benefits and harms. Preface.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Common | 2012 |
Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplas | 2012 |
Interleukin genes and associations with colon and rectal cancer risk and overall survival.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Body Mass Index; C | 2013 |
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Aspirin; ATP Binding Cassette Transporter, S | 2012 |
Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors.
Topics: Animals; Aspirin; Cell Proliferation; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplas | 2012 |
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Asp | 2013 |
Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Female | 2012 |
Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Proliferation; Chromatography, | 2013 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic | 2013 |
COX-2-independent antiproliferative action of acetylsalicylic acid in human colon cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Division; Colonic Neoplasms; Cyclooxygenase 2 | 2002 |
The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Carcinoembryonic Antigen; Cell Division | 2002 |
On call. I've read that aspirin may help prevent colon cancer as well as heart attacks. I take an aspirin every day, and I wonder if it may also help with prostate cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Humans | 2002 |
A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blotting, Western; Cell Cycle; Cell Div | 2003 |
Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer.
Topics: Active Transport, Cell Nucleus; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; As | 2003 |
Blocking colon cancer. An aspirin a day helps.
Topics: Aspirin; Colonic Neoplasms; Female; Humans; Male; United States | 2003 |
Relationship between apoptosis, angiogenesis and colon-26 tumour growth after oral NSAID-treatment.
Topics: Adenocarcinoma; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; A | 2002 |
NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cell Cycle; Cell Division; Cell Survival; Colonic | 2003 |
Aspirin curbs colon polyps. But for many, bleeding risks may offset benefits.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colonic Polyps; Gastrointestina | 2003 |
Prostaglandin-independent effects of aspirin on cell cycle and putrescine synthesis in human colon carcinoma cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Caco-2 Ce | 2003 |
Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin.
Topics: Aspirin; beta Catenin; Blotting, Northern; Butyrates; Cell Division; Colonic Neoplasms; Cytoskeletal | 2003 |
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2003 |
Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells.
Topics: Apoptosis; Aspirin; Base Sequence; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclic AMP; C | 2003 |
[Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells].
Topics: Adenocarcinoma; Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Cel | 2003 |
The noise stops you from hearing good music: the possibilities for a mortality reduction program for cancer of the colon and rectum in São Paulo.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brazil; Colonic Neoplasms; Cost-Benefit Analysis; | 2003 |
Aspirin inhibits endothelial nitric oxide synthase (eNOS) and Flk-1 (vascular endothelial growth factor receptor-2) prior to rat colon tumour development.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Azoxymethane; Caspase 3; Caspa | 2004 |
Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Cells, Cultured; Collagen; Colo | 2003 |
Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association.
Topics: Aspirin; beta Catenin; Cadherins; Colonic Neoplasms; Cytoskeletal Proteins; Genes, Reporter; Humans; | 2003 |
Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemopreventi
Topics: Aspirin; beta Catenin; Cell Nucleus; Colonic Neoplasms; Cyclic GMP; Cyclooxygenase 2; Cytoskeletal P | 2003 |
NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Body Weight; Cel | 2004 |
DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Dose-Response Relation | 2004 |
Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Humans; Intesti | 2004 |
Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
Topics: Apoptosis; Aspirin; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Growth | 2005 |
Influence of rofecoxib on experimental colonic carcinogenesis in rats.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Carcinogens; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxyg | 2004 |
Preventing colon cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium, Dietary; Colonic Neoplasms; Colonic Polyp | 2005 |
In vivo measurement of DNA synthesis rates of colon epithelial cells in carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Azoxymethane; Bo | 2005 |
Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Line, Tu | 2005 |
Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Line, Tumor; Cell Proliferation; C | 2006 |
NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
Topics: Adenocarcinoma; Aspirin; Base Sequence; Catalysis; Colonic Neoplasms; DNA Primers; HT29 Cells; Human | 2005 |
Low-dose aspirin reduces risk of colon cancers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Humans; Intestinal Polyps | 2005 |
NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Proliferation; Cell Trans | 2006 |
Randomized trial of aspirin, vitamin E raises questions for future chemoprevention studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidants; Aspirin; Behavior Th | 2005 |
Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation.
Topics: Aspirin; Blotting, Western; Cell Cycle; Cell Death; Cell Proliferation; Colonic Neoplasms; Enzyme Ac | 2006 |
Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Aspirin; Blotting, Western; Caspase 3; Caspase 8; Caspase | 2005 |
Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells.
Topics: Acetyltransferases; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caco-2 Cells; Colonic Neoplasm | 2006 |
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2005 |
NO-donating aspirin induces phase II enzymes in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Aspirin; Chemoprevention; Colonic Neoplasms; Enzyme Induction; Female; Glut | 2006 |
Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress.
Topics: Adenocarcinoma; Adherens Junctions; Animals; Antineoplastic Agents; Apoptosis; Aspirin; beta Catenin | 2005 |
[Characteristics of colon cancer diagnosed in patients taking aspirin or warfarin].
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Female; Gastrointestinal | 2005 |
[Aspirin, is it effective for prevention of colon cancer?].
Topics: Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Humans | 2005 |
Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Colonic Neoplas | 2006 |
PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; California; Case-Control Studies; Col | 2006 |
COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African American; Colonic Neoplasms | 2006 |
Aspirin use cuts colon cancer risk, but may have side effect.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Female | 2006 |
Does regular use of aspirin reduce the risk of colorectal cancer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Female; Humans; Prospective Stu | 2006 |
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celec | 2006 |
Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Survival; Col | 2006 |
Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Case-C | 2006 |
Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets.
Topics: Acetates; Animals; Antineoplastic Agents; Aspirin; Azoxymethane; beta Catenin; Carcinogens; Colonic | 2006 |
Cyclooxygenase-independent effects of aspirin on HT-29 human colon cancer cells, revealed by oligonucleotide microarrays.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Biotechnology; Cluster Analysis; Coloni | 2006 |
Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1.
Topics: Aspirin; Blotting, Western; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Cyclooxygenase 1; Hu | 2006 |
[Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells].
Topics: Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygena | 2006 |
Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Female; Follow-Up Studies | 2006 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM.
Topics: Apoptosis; Aspirin; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Division; Cell | 2007 |
Follow-up of tumor development in the colons of living rats and implications for chemoprevention trials: assessment of aspirin-difluoromethylornithine combination.
Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspi | 2007 |
IL6 genotypes and colon and rectal cancer.
Topics: Adult; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Female; G | 2007 |
Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Line, Tumor; Colonic Neoplasms; Hu | 2007 |
Leptin and leptin receptor genotypes and colon cancer: gene-gene and gene-lifestyle interactions.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2008 |
How to lower your risk for colon cancer. The search for answers circles back to some familiar recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Body Weight; Calcium, Die | 2007 |
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.
Topics: Aspirin; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Glycogen Synth | 2008 |
Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells.
Topics: 4-Butyrolactone; Adenocarcinoma; Aspirin; Caco-2 Cells; Cell Growth Processes; Colonic Neoplasms; Cy | 2008 |
Contraceptive patch: new labeling.
Topics: Administration, Cutaneous; Adolescent; Anti-HIV Agents; Aspirin; Colonic Neoplasms; Contraceptive Ag | 2008 |
Transcription factor 7-like 2 polymorphism and colon cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Female; Humans; Ma | 2008 |
Evaluation for colon cancer in patients with occult fecal blood loss while taking aspirin: a Bayesian viewpoint.
Topics: Adult; Aged; Aspirin; Bayes Theorem; Colonic Neoplasms; Feces; Humans; Male; Middle Aged; Occult Blo | 1982 |
Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing.
Topics: Aspirin; Colonic Neoplasms; Feces; Female; Humans; Male; Occult Blood; Rectal Neoplasms | 1982 |
Clinical development plan: aspirin.
Topics: Aspirin; Clinical Trials as Topic; Colonic Neoplasms; Drug Approval; Drug Evaluation, Preclinical; H | 1994 |
Aspirin and the risk of colorectal cancer in women.
Topics: Adult; Aspirin; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Middle Aged | 1995 |
Use of low-dose aspirin as a preventive measure.
Topics: Aspirin; Colonic Neoplasms; Coronary Disease; Humans | 1995 |
Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Aspirin; Base Sequence; Cell Line; Colonic Neoplasms; Dinoprost; Dinoprostone; DNA P | 1995 |
Chemopreventive effects of calcium but not aspirin supplementation in cholic acid-promoted colon carcinogenesis: correlation with intermediate endpoints.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Biomarkers, Tumor; Body Weight; Calcium; Ch | 1995 |
Aspirin prevention update: new data on lung and colon cancers.
Topics: Adenoma; Animals; Aspirin; Colonic Neoplasms; Humans; Lung Neoplasms; Mice | 1995 |
Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon.
Topics: Acetaminophen; Adenoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1995 |
Aspirin versus colonoscopy in the reduction of carcinoma of the colon.
Topics: Adult; Aged; Aspirin; Carcinoma; Cohort Studies; Colonic Neoplasms; Colonoscopy; Humans; Male; Middl | 1995 |
NSAIDs and the chemoprevention of colon and oesophageal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Esophageal Neoplasms; Humans; P | 1995 |
Diseases preceding colon cancer. A case-control study among veterans.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Female; H | 1994 |
Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model.
Topics: Animals; Aspirin; Colonic Neoplasms; Dimethylhydrazines; Disease Models, Animal; Dose-Response Relat | 1994 |
[Does aspirin reduce the risk of colorectal polyps and cancer?].
Topics: Aspirin; Colonic Neoplasms; Colonic Polyps; Humans; Risk | 1994 |
Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Aspirin; Body Weight; Carcinogens; Cell Div | 1994 |
A broad anticancer effect of aspirin?
Topics: Aspirin; Breast Neoplasms; Colonic Neoplasms; Confounding Factors, Epidemiologic; Female; Humans; Lu | 1994 |
Therapeutic potential of aspirin in cancer of the colon.
Topics: Aspirin; Colonic Neoplasms; Humans | 1993 |
Altered eicosanoid levels in human colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; | 1993 |
Aspirin and non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colonic Polyps; Female | 1993 |
Aspirin's next conquest: does it prevent colon cancer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Humans | 1994 |
Aspirin and risk of fatal colon cancer.
Topics: Aspirin; Colonic Neoplasms; Humans; Risk Factors | 1993 |
Aspirin use, cancer, and polyps of the large bowel.
Topics: Aspirin; Case-Control Studies; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administrat | 1993 |
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Body Weight; Colon | 1993 |
Aspirin and colorectal cancer.
Topics: Aspirin; Colonic Neoplasms; Humans; Rectal Neoplasms; Risk Factors | 1993 |
Aspirin use and risk of fatal cancer.
Topics: Acetaminophen; Aspirin; Colonic Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Female; | 1993 |
Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group.
Topics: Adenoma; Aged; Aspirin; Colonic Neoplasms; Colonoscopy; Female; Humans; Male; Middle Aged; Surveys a | 1993 |
Aspirin and risk of fatal colon cancer.
Topics: Aspirin; Colonic Neoplasms; Humans | 1993 |
Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.
Topics: Animals; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Liver Neoplasms, | 1995 |
Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; CDC2 Protein Kinase; CD | 1996 |
Effects of dietary fibre on dimethylhydrazine-induced changes in prostanoid concentrations in rat colonic mucosa.
Topics: 1,2-Dimethylhydrazine; 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Carcinogens; Chromatography, | 1995 |
Aspirin and colon cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Colonic Neoplasms; Colorectal | 1996 |
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cell Li | 1996 |
Aspirin use and fecal occult blood testing.
Topics: Aspirin; Colonic Neoplasms; Humans; Mass Screening; Occult Blood; Sensitivity and Specificity | 1996 |
Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung.
Topics: Animals; Antineoplastic Agents; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibitors; Docosahexaeno | 1997 |
Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats.
Topics: 1,2-Dimethylhydrazine; 16,16-Dimethylprostaglandin E2; Animals; Anti-Inflammatory Agents, Non-Steroi | 1997 |
Are dietary factors involved in DNA methylation associated with colon cancer?
Topics: Aged; Aging; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studie | 1997 |
Aspirin for bowel cancer: an old friend finds a new role.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibitors; Huma | 1997 |
Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein A-I; Apoptosis; Aspirin; Blo | 1997 |
Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apopt | 1998 |
Acromegaly and colonic cancer.
Topics: Acromegaly; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Col | 1997 |
Apoptosis induction and inhibition of colon-26 tumour growth and angiogenesis: findings on COX-1 and COX-2 inhibitors in vitro & in vivo and topical diclofenac in hyaluronan.
Topics: Administration, Topical; Animals; Apoptosis; Aspirin; Cell Division; Cell Survival; Colonic Neoplasm | 1997 |
Aspirin-like molecules that covalently inactivate cyclooxygenase-2.
Topics: Acetylation; Acetylene; Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Binding | 1998 |
Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Aspirin; Azoxymethane; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase | 1998 |
Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplas | 1998 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aspirin; Cell Cycle; Cell Division; Colonic Neoplasms; | 1998 |
Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Colon; Colonic Neoplasms; Diet | 1998 |
Colorectal cancer--chemoprevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Folic Acid; Humans; Rectal Neop | 1998 |
Aspirin and colon cancer prevention.
Topics: Animals; Aspirin; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred C5 | 1998 |
Association between coronary heart disease and cancers of the breast, prostate, and colon.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Colo | 1998 |
Chemopreventive effect of aspirin on growth of aberrant crypt foci in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azoxymethane; Carcinogens; Chemopreventio | 1998 |
Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arachidonic Acid; Aspirin; Colon; Colonic Neo | 1997 |
Cell-type-specific activation of c-Jun N-terminal kinase by salicylates.
Topics: Acetaminophen; Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium-Ca | 1999 |
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
Topics: Animals; Aspirin; Azoxymethane; Colon; Colonic Neoplasms; Dinoprostone; Dose-Response Relationship, | 1999 |
Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in rats.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Carcinogens; Chemoprevention; Colonic Neoplasms; Male; Neop | 1999 |
Colon cancer prevention. Worth the trouble.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colonic Neoplasms; Diet; Female; | 1999 |
Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells.
Topics: Adenocarcinoma; Adenoviruses, Human; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Ce | 2000 |
Aspirin and salicylate: An old remedy with a new twist.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; CCAAT-Enhancer-Binding Protein-beta; Colonic Neopl | 2000 |
Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Cycle; Cell Size; Cell | 2000 |
[Aminosalicylates and aspirin for colonic cancer: from anti-inflammatory to antineoplastic drugs?].
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Colonic Neoplasms; DNA Damage; Humans; Mesalamine; Treatm | 2000 |
Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin | 2001 |
CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic | 2001 |
Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells.
Topics: Active Transport, Cell Nucleus; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apop | 2001 |
Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Calcium; Cell Cycle; Cell Division; Cel | 2001 |
Trans-fatty acids and colon cancer.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Diet Records; Dietary Fat | 2001 |
Expression profile analysis of colon cancer cells in response to sulindac or aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Down-R | 2002 |
[The effects of butyrates and non-steroidal anti-inflammatory agents on HT-29 colonic carcinoma cells].
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Colonic Neop | 2002 |
Gastrocolic fistula as a complication of benign gastric ulcer.
Topics: Adult; Aged; Aspirin; Barium Sulfate; Colonic Diseases; Colonic Neoplasms; Diagnosis, Differential; | 1976 |
Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Colonic Neoplasms; Cyclic AMP; Dimethylhydrazines; Dinopros | 1992 |
Aspirin use and reduced risk of fatal colon cancer.
Topics: Aspirin; Colonic Neoplasms; Humans | 1992 |
Aspirin use and reduced risk of fatal colon cancer.
Topics: Acetaminophen; Adult; Aspirin; Colonic Neoplasms; Humans | 1992 |
Aspirin use and reduced risk of fatal colon cancer.
Topics: Aspirin; Colonic Neoplasms; Female; Humans; Male | 1992 |
Aspirin use and reduced risk of fatal colon cancer.
Topics: Acetaminophen; Adult; Aspirin; Cohort Studies; Colonic Neoplasms; Female; Humans; Male; Middle Aged; | 1991 |
Aspirin use and incidence of large-bowel cancer in a California retirement community.
Topics: Aspirin; Bias; California; Colonic Neoplasms; Female; Humans; Incidence; Male; Prospective Studies | 1991 |
Could aspirin really prevent colon cancer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Humans; Research Design; Risk | 1991 |